Scarica l'app Stockscreener
50.11
0.32%
0.16
Dopo l'orario di chiusura:
50.37
0.26
+0.52%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$49.95
Aprire:
$50.63
Volume 24 ore:
460.03K
Relative Volume:
0.64
Capitalizzazione di mercato:
$2.89B
Reddito:
$718.95M
Utile/perdita netta:
$-38.55M
Rapporto P/E:
-73.27
EPS:
-0.6839
Flusso di cassa netto:
$45.99M
1 W Prestazione:
-1.67%
1M Prestazione:
+0.40%
6M Prestazione:
+1.81%
1 anno Prestazione:
+58.58%
Intervallo 1D:
$49.76
$51.03
Intervallo di 1 settimana:
$49.65
$52.37
Portata 52W:
$29.16
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
50.11 | 2.92B | 718.95M | -38.55M | 45.99M | -0.6839 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
MACD Signal: Is Supernus Pharmaceuticals Inc part of any major index2026 Year in Review & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals - National Today
Responsive Playbooks and the SUPN Inflection - Stock Traders Daily
Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts - Yahoo Finance UK
Supernus Pharmaceuticals (SUPN) Enters $350M Asset Purchase Agre - GuruFocus
Supernus Pharmaceuticals Acquires NV-5138 (SPN-820) Compound from Navitor Pharmaceuticals in Asset Purchase Agreement - Minichart
Supernus enters into asset purchase agreement with Navitor - TipRanks
Supernus (SUPN) Acquires Key Assets from Navitor Pharmaceuticals - GuruFocus
Supernus Acquires NV-5138 Asset in New Agreement - TipRanks
Supernus Pharmaceuticals Inc Enters Asset Purchase Agreement With Navitor On April 1, 2026 - TradingView — Track All Markets
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals has reached an agreement to acquire the asset portfolio related to the candidate drug NV-5138 (also known as SPN-820). - Bitget
[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
RSI Check: Is Supernus Pharmaceuticals Inc a stock for growth or value investorsWeekly Stock Recap & Comprehensive Market Scan Reports - baoquankhu1.vn
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN
Supernus Pharmaceuticals Inc (S49.DU) stock price, news, quote and history - Yahoo Finance UK
Understanding the Setup: (SUPN) and Scalable Risk - Stock Traders Daily
Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year - aol.com
Hennion & Walsh Asset Management Inc. Has $4.01 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Tudor Investment Corp ET AL Makes New Investment in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co. - MarketBeat
Market Trends: Is now the right time to enter Supernus Pharmaceuticals IncWall Street Watch & High Yield Equity Trading Tips - baoquankhu1.vn
Vanguard disaggregates holdings after internal realignment (SUPN) - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
D&O policy doesn’t cover antitrust suit over drug acquisition: Court - businessinsurance.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Insurer Need Not Cover Parkinson's Drug Antitrust Dispute - Law360
Jefferies reiterates Supernus Pharmaceuticals stock Buy rating By Investing.com - Investing.com India
Jefferies reiterates Supernus Pharmaceuticals stock Buy rating - Investing.com UK
Breakout Watch: What is the target price for Supernus Pharmaceuticals Inc stockQuarterly Growth Report & Low Volatility Stock Suggestions - baoquankhu1.vn
SUPN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
The Technical Signals Behind (SUPN) That Institutions Follow - Stock Traders Daily
SUPN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SUPN Technical Analysis & Stock Price Forecast - Intellectia AI
Quarterly Risk: Does Supernus Pharmaceuticals Inc have strong EBITDA margins2026 Technicals & High Accuracy Buy Signal Tips - baoquankhu1.vn
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells 7,250 Shares of Stock - MarketBeat
Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells $2,514,000.00 in Stock - MarketBeat
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Supernus Pharmaceuticals Q4 2025 earnings preview - MSN
SUPN (NASDAQ: SUPN) Form 144 lists 57,250-share resale after option exercise - Stock Titan
SUPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Supernus Pharmaceuticals CEO Sells $1.76M in Stock - National Today
Insider Sell Alert: Frederick Hudson Sells Shares of Supernus Ph - GuruFocus
[144] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Supernus (NASDAQ: SUPN) CEO-linked KBT Trust sells 35,000 shares under 10b5-1 plan - Stock Titan
Director at Supernus (NASDAQ: SUPN) sells 5,369 shares - Stock Titan
SUPN SEC FilingsSupernus Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Mixed Short And Long Term Returns - simplywall.st
Aristotle Capital Boston LLC Sells 503,122 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
1.06%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):